Concord Drugs (BOM:538965) E10: ₹1.18 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:538965 Concord Drugs Ltd BOM:538965
67 GF Score
Price ₹71.23
GF Value ₹60.93
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Concord Drugs E10?

Concord Drugs BOM:538965 +1.38% 67 E10 is ₹1.18 as of Mar. 2026. GuruFocus rates BOM:538965 with a GF Score™ of 67/100 and a GF Value™ of ₹60.93 (Modestly Overvalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Concord Drugs's adjusted earnings per share data for the three months ended in Mar. 2026 was ₹0.470. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ₹1.18 for the trailing ten years ended in Mar. 2026.

During the past 12 months, Concord Drugs's average E10 Growth Rate was -28.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-08-05), Concord Drugs's current stock price is ₹71.23. Concord Drugs's E10 for the quarter that ended in Mar. 2026 was ₹1.18. Concord Drugs's Shiller PE Ratio of today is 60.36.

During the past 13 years, the highest Shiller PE Ratio of Concord Drugs was 72.87. The lowest was 17.76. And the median was 22.72.


Concord Drugs  (BOM:538965) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

Concord Drugs's Shiller P/E Ratio of today is calculated as

Shiller PE Ratio=Share Price/E10
=71.23/1.18
=60.36

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Shiller P/E Ratio of Concord Drugs was 72.87. The lowest was 17.76. And the median was 22.72.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Concord Drugs E10 Related Terms


Concord Drugs E10 Historical Data

* Premium members only.

The historical data trend for Concord Drugs's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Concord Drugs E10 Chart

Concord Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 1.72 1.65 1.18

Concord Drugs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.65 1.63 1.62 1.24 1.18

BOM:538965 vs ZTS: E10 Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Concord Drugs's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Concord Drugs Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Concord Drugs's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Concord Drugs's Shiller PE Ratio falls into.


BOM:538965
67GF Score
Concord Drugs Ltd BOM:538965
E10 is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Concord Drugs E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Concord Drugs's adjusted earnings per share data for the three months ended in Mar. 2026 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.47/164.2724*164.2724
=0.470

Current CPI (Mar. 2026) = 164.2724.

Concord Drugs Quarterly Data

per share eps CPI Adj_EPS
201606 0.160 105.961 0.248
201609 0.480 105.961 0.744
201612 1.830 105.196 2.858
201703 -2.450 105.196 -3.826
201706 -0.010 107.109 -0.015
201709 0.080 109.021 0.121
201712 0.410 109.404 0.616
201803 -0.170 109.786 -0.254
201806 0.160 111.317 0.236
201809 0.050 115.142 0.071
201812 0.050 115.142 0.071
201903 0.260 118.202 0.361
201906 0.150 120.880 0.204
201909 0.060 123.175 0.080
201912 0.050 126.235 0.065
202003 0.110 124.705 0.145
202006 0.190 127.000 0.246
202009 0.092 130.118 0.116
202012 3.090 130.889 3.878
202103 0.386 131.771 0.481
202106 0.790 134.084 0.968
202109 0.520 135.847 0.629
202112 0.480 138.161 0.571
202203 0.030 138.822 0.035
202206 0.210 142.347 0.242
202209 0.210 144.661 0.238
202212 0.520 145.763 0.586
202303 0.120 146.865 0.134
202306 0.530 150.280 0.579
202309 0.600 151.492 0.651
202312 -0.240 152.924 -0.258
202403 -0.340 153.035 -0.365
202406 0.030 155.789 0.032
202409 0.040 157.882 0.042
202412 0.230 158.323 0.239
202503 0.040 157.552 0.042
202506 0.120 159.755 0.123
202509 0.190 162.289 0.192
202512 0.160 163.281 0.161
202603 0.470 164.272 0.470

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ₹1.18 mean?
Concord Drugs (BOM:538965) has a E10 of ₹1.18 as of Mar. 2026. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Concord Drugs and its competitors.
Is Concord Drugs' E10 too high?
Concord Drugs' current E10 is ₹1.18. Overall, Concord Drugs has a GF Score™ of 67/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Concord Drugs' E10 compare to ZTS?
Concord Drugs' E10 of ₹1.18 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Concord Drugs and its competitors. Concord Drugs's current E10 is ₹1.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Concord Drugs stock overvalued right now?
Based on GuruFocus' analysis, Concord Drugs (BOM:538965) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹60.93, compared to a current price of ₹71.23 — trading 16.9% above its estimated fair value. The current E10 is ₹1.18. Concord Drugs' overall GF Score™ is 67/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Concord Drugs (BOM:538965), the current E10 is ₹1.18 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Concord Drugs (BOM:538965) Overvalued in 2026?

Based on GuruFocus' analysis, Concord Drugs stock appears to be overvalued. The current stock price of ₹71.23 is trading 16.9% above its estimated GF Value™ of ₹60.93. GuruFocus considers Concord Drugs to be Modestly Overvalued.

Key valuation signals for BOM:538965:

  • E10: ₹1.18
  • GF Value™: ₹60.93 vs. price of ₹71.23 (16.9% above fair value)
  • GF Score™: 67/100 with 5 warning signs

No single metric tells the full story. See the BOM:538965 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Concord Drugs Business Description

Address Survey No. 249, Brahmanapally Village, Hayatnagar Mandal, Ranga Reddy, Hyderabad, TG, IND, 501511
Concord Drugs Ltd is an India based pharmaceutical company. The principal activity of the company is to manufacture licensed drugs based on the formulations approved. Its product portfolio includes Pharmaceutical Ready to fill Pellets, MUPS ((Multiple Unit Pellets System); Tissue Bio Adhesive; Injectables (Small Volume Parenterals); Capsules; Liquid Orals (Syrups & Suspensions); Dry Syrups (Powder) and Hand Sanitizers.
67GF Score

Get the complete analysis for BOM:538965

E10 is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹71.23
Price
₹60.93
GF Value